Trial · NCT02954991
Results by group15
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 15 of 15
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Objective Response Rate (ORR) as Defined by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. | CIT Experienced: Sitravatinib and Nivolumab | 15.3 | 95% Confidence Interval 9.5 to 22.9 | percentage of participants | |
| Objective Response Rate (ORR) as Defined by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. | CIT Naïve: Sitravatinib and Nivolumab | 25 | 95% Confidence Interval 11.5 to 43.4 | percentage of participants | |
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) | CIT Experienced: Sitravatinib and Nivolumab | 123 | Participants | ||
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) | CIT Naïve: Sitravatinib and Nivolumab | 32 | Participants | ||
| Duration of Response (DOR) | CIT Experienced: Sitravatinib and Nivolumab | 11.0 | 95% Confidence Interval 3.7 to 13.1 | months | |
| Duration of Response (DOR) | CIT Naïve: Sitravatinib and Nivolumab | 11.1 | 95% Confidence Interval 3.7 to NA | months | |
| Progression Free Survival (PFS) | CIT Experienced: Sitravatinib and Nivolumab | 5.4 | 95% Confidence Interval 4.2 to 5.7 | months | |
| Progression Free Survival (PFS) | CIT Naïve: Sitravatinib and Nivolumab | 7.1 | 95% Confidence Interval 4.0 to 13.1 | months | |
| Overall Survival (OS) | CIT Experienced: Sitravatinib and Nivolumab | 11.5 | 95% Confidence Interval 8.7 to 15.0 | months | |
| Overall Survival (OS) | CIT Naïve: Sitravatinib and Nivolumab | NA | 95% Confidence Interval 9.8 to NA | months | |
| Blood Plasma Concentrations | Cycle 1 Day 15 | 76.57 | Standard Deviation 51.041 | ng/ml | |
| Blood Plasma Concentrations | Cycle 2 Day 1 | 59.25 | Standard Deviation 36.759 | ng/ml | |
| Blood Plasma Concentrations | Cycle 2 Day 15 | 52.87 | Standard Deviation 26.265 | ng/ml | |
| Blood Plasma Concentrations | Cycle 3 Day 1 | 46.41 | Standard Deviation 26.183 | ng/ml | |
| Blood Plasma Concentrations | Cycle 5 Day 1 | 30.04 | Standard Deviation 12.239 | ng/ml |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02954991/results